Bio-Techne Corporation (TECH)
74.74
-1.68 (-2.20%)
At close: Jan 14, 2025, 3:59 PM
undefined% (undefined)
| Bid | 67.1 |
| Market Cap | 11.88B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.95 |
| PE Ratio (ttm) | 78.67 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 80.67 |
| Volume | 1,075,408 |
| Avg. Volume (20D) | 898,439 |
| Open | 76.48 |
| Previous Close | 76.42 |
| Day's Range | 74.15 - 78.44 |
| 52-Week Range | 61.16 - 85.57 |
| Beta | undefined |
About TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene ther...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 9, 1989
Employees 3,100
Stock Exchange NASDAQ
Ticker Symbol TECH
Website https://www.bio-techne.com
Analyst Forecast
According to 8 analyst ratings, the average rating for TECH stock is "Buy." The 12-month stock price forecast is $85, which is an increase of 13.73% from the latest price.
Buy 62.50%
Hold 37.50%
Sell 0.00%
Next Earnings Release
Bio-Techne Corporation is scheduled to release its earnings on Jan 30, 2025,
before market opens.
Analysts project revenue of $286.03M, reflecting a 4.93% YoY growth and earnings per share of 0.39, making a -2.50% decrease YoY.
Analysts project revenue of $286.03M, reflecting a 4.93% YoY growth and earnings per share of 0.39, making a -2.50% decrease YoY.
1 month ago ·
Source
+4.36%
Bio-Techne shares are trading higher after Gemini ...
Unlock content with
Pro Subscription
1 month ago ·
Source
+3.54%
Bio-Techne shares are trading higher after the company announced it partnered with Life Sciences to distribute its portfolio across the Arab Gulf states.
